Bone marrow-derived mesenchymal stem cell-derived exosome-loaded miR-129-5p targets high-mobility group box 1 attenuates neurological-impairment after diabetic cerebral hemorrhage

Figure 9 MicroRNA-129-5p targeted and regulated high mobility group box 1 expression. A: Bioinformatic analysis of binding sites of microRNA (miR-129-5p) and high mobility group box 1 (HMGB1) 3’ untranslated region; B: A dual luciferase reporter gene assay was used to verify the specific binding of miR-129-5p and HMGB1. Experimental data are expressed as mean ± SD. ^aP < 0.05, negative control (NC) group vs mmu-miR-129-5p group, t-test; C: RNA binding protein immunoprecipitation assay verified the specific binding of miR-129-5p and HMGB1. Experimental data are expressed as mean ± SD. ^aP < 0.05, AGO-2 vs immunoglobulin G (IgG) (HMGB1 group); ^bP < 0.01, AGO-2 vs IgG (miR-129-5p group), t-test; D: The expression of HMGB1 was detected by quantitative polymerase chain reaction in vitro and in vivo, and the experimental data are expressed as mean ± SD. In vivo: ^aP < 0.05, intracerebral hemorrhage (ICH) + diabetes mellitus (DM) group vs ICH + DM + bone marrow-derived mesenchymal stem cell-derived exosomes (BMSC-exo) group; ^aP < 0.05, ICH +DM + BMSC-exo group vs ICH + DM + miR-129-5p inhibitor group; ^aP < 0.05, ICH + DM + miR-129-5p inhibitor group vs ICH +DM + miR-129-5p inhibitor NC group, t-test. In vitro: ^aP < 0.05, high glucose (HG) + hemin group vs HG + hemin + BMSC-exo group; ^aP < 0.05, HG + hemin + BMSC-exo group vs HG + hemin + miR-129-5p inhibitor group; ^aP < 0.05, HG + hemin + miR-129-5p inhibitor group vs HG + hemin + miR-129-5p inhibitor NC group, t-test. BMSC-exo: Bone marrow-derived mesenchymal stem cell-derived exosomes; HG: High glucose; NC: Negative control; ICH: Intracerebral hemorrhage; DM: Diabetes mellitus; HMGB1: High-mobility group box 1; DM: Diabetes mellitus; ICH: Intracerebral hemorrhage; IgG: Immunoglobulin G.